title: Presentation of antigens internalized through the B cell receptor requires newly synthesized MHC class II molecules.
abstract: Exogenous Ags taken up from the fluid phase can be presented by both newly synthesized and recycling MHC class II molecules. However, the presentation of Ags internalized through the B cell receptor (BCR) has not been characterized with respect to whether the class II molecules with which they become associated are newly synthesized or recycling. We show that the presentation of Ag taken up by the BCR requires protein synthesis in splenic B cells and in B lymphoma cells. Using B cells transfected with full-length I-Ak molecules or molecules truncated in cytoplasmic domains of their alpha- or beta-chains, we further show that when an Ag is internalized by the BCR, the cytoplasmic tails of class II molecules differentially control the presentation of antigenic peptides to specific T cells depending upon the importance of proteolytic processing in the production of that peptide. Integrity of the cytoplasmic tail of the I-Ak beta-chain is required for the presentation of the hen egg lysozyme determinant (46-61) following BCR internalization, but that dependence is not seen for the (34-45) determinant derived from the same protein. The tail of the beta-chain is also of importance for the dissociation of invariant chain fragments from class II molecules. Our results demonstrate that Ags internalized through the BCR are targeted to compartments containing newly synthesized class II molecules and that the tails of class II beta-chains control the loading of determinants produced after extensive Ag processing.
authors: Centre d'Immunologie de Marseille-Luminy, France. forquet@ciml.univ-mrs.fr
authors: F
authors: F
authors: Forquet
authors: N
authors: N
authors: Barois
authors: P
authors: P
authors: Machy
authors: J
authors: J
authors: Trucy
authors: V S
authors: VS
authors: Zimmermann
authors: L
authors: L
authors: Leserman
authors: J
authors: J
authors: Davoust
mesh_terms: D000818:Animals; D017951:Antigen Presentation / Q000187:drug effects / Q000235:genetics; D002460:Cell Line; D003513:Cycloheximide / Q000494:pharmacology; D003593:Cytoplasm / Q000378:metabolism; D004527:Egg Proteins / Q000276:immunology* / Q000378:metabolism; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis* / Q000235:genetics / Q000502:physiology*; D007424:Intracellular Fluid / Q000378:metabolism; D008081:Liposomes / Q000378:metabolism; D016393:Lymphoma, B-Cell; D051379:Mice; D008808:Mice, Inbred CBA; D008822:Mice, Transgenic; D009113:Muramidase / Q000276:immunology* / Q000378:metabolism; D009154:Mutation; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D011485:Protein Binding / Q000276:immunology; D011947:Receptors, Antigen, B-Cell / Q000378:metabolism*
chemical_list: D004527:Egg Proteins; D000949:Histocompatibility Antigens Class II; D008081:Liposomes; D010446:Peptide Fragments; D011947:Receptors, Antigen, B-Cell; D003513:Cycloheximide; D009113:Muramidase